Primex Pharmaceuticals appoints Steen Vangsgaard as Head of Sales
Steen Vangsgaard has joined Primex Pharmaceuticals from Mylan Pharmaceuticals, where he was VP, Area Director. Prior to Mylan, Mr. Vangsgaard was EVP, Commercial Affairs at Bavarian-Nordic. He has extensive international leadership experience in growing sales and enhancing profitability of generics, branded pharmaceuticals and OTC portfolios. Additionally, he has background in business development and operational side of business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180905005544/en/
Swiss pharmaceutical company Primex Pharmaceuticals AG announces the expansion of the leadership team with Mr. Steen Vangsgaard, appointed as Head of Sales to the Executive Management Team led by CEO Kari Sarvanto. (Photo: Business Wire)
“I look forward to working with our sales and distribution partners in anticipation of making ADV6209 available to children who face surgical intervention and emergency treatment. It is particularly gratifying to join Primex at a time where we are preparing to help reduce pre- and post-operative trauma in children and improve efficiency in trauma centres and operating theatres,” says Steen Vangsgaard.
At Primex, Mr. Vangsgaard is responsible for global sales. His first effort will be the sales force and launch of ADV6209 in the Nordics. He will be part of the Executive Team headed by CEO Kari Sarvanto in Zug, Switzerland.
Mr. Sarvanto comments: “I am pleased that Primex can attract top talent such as Steen. We are a fast growth company and with the impending launch of ADV6209, the first oral paediatric anaesthetic in Europe, for both premedication and procedural sedation, Steen will help us to accelerate our launches in Europe, internationally and in the US.”
About Primex Pharmaceuticals
Primex Pharmaceuticals aims to become the leading global innovative anaesthesia company, and to expand in paediatric pharmaceuticals.
A portfolio of strong, trusted anaesthesia products from propofol-based products acquired from Bayer, to a novel oral solution for paediatric procedural sedation, helping patients undergo a wide range of medical procedures. Primex Pharmaceuticals will continue to identify and acquire new medications that complete the ‘Triad of Anaesthesia’. The group includes a range of dental products and anaesthetics under the OGNA brand.
Primex Pharmaceuticals' global partner network operates in over 40 countries. The company is headquartered in Switzerland; all Primex products are manufactured in Europe. Primex Pharmaceuticals has proven underlying business operations and historical strong revenue growth.
See more at www.primexpharma.com
Primex Pharmaceuticals AG
Mr. Kari Sarvanto, Group CEO
Mobile: +41 796 162 694
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pacific Drilling Successfully Emerges from Chapter 11 Proceedings19.11.2018 20:18 | Pressemelding
Pacific Drilling S.A. (OTC: PACDQ) (the “Company”) announced that effective today the Company and certain of its affiliated chapter 11 debtors have emerged from bankruptcy after successfully completing restructuring transactions pursuant to their chapter 11 plan of reorganization (the “Plan”). In connection with emergence from bankruptcy, the Company raised $1.5 billion in gross proceeds in new capital, consisting of $1.0 billion of new secured notes and $500 million of equity. Pursuant to the Plan, the Company equitized approximately $1.85 billion in pre-petition debt associated with the Company’s Term Loan B, 2017 Notes and 2020 Notes, and paid in full approximately $1.2 billion of debt related to its pre-petition senior secured credit facility, revolving credit facility and the post-petition debtor-in-possession financing. Customer, employee and ordinary trade claims were unimpaired. The Plan has strengthened the Company’s balance sheet by significantly reducing its leverage and enh
Tempo Announces New Majority Ownership by Diversis Capital19.11.2018 20:10 | Pressemelding
Tempo, a leader in productivity-enhancing project management solutions, today welcomes Diversis Capital as a new strategic owner with a controlling interest in the company. Former owner and founder, Origo, will retain a 45% stake in Tempo, and remains an important partner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181119005782/en/ “We are very pleased to announce new ownership by Diversis Capital with their wide experience of working with unique tech companies and the tremendous opportunity for growth that this brings,” said Agust Einarsson, CEO of Tempo. “Diversis has demonstrated their value to investments through its collaborative approach using their operating partner and strategic advisors working alongside management to take companies to the next level. Additional financial support will lend further strength to Tempo’s global growth.” Created in 2007 as an internal tool to track time utilization and management on
Valence Advises Golden Gate on Acquisition of Active Minerals19.11.2018 19:07 | Pressemelding
The Valence Group acted as financial advisor to Golden Gate Capital on its announced acquisition of Active Minerals International from Merit Capital Partners. Financial terms of the transaction were not disclosed. About Active Minerals International Active Minerals International LLC (AMI) is a worldwide leader in the production and marketing of kaolin and gel quality attapulgite clay minerals. Its products are sold throughout the world for industrial, agricultural and construction related applications. AMI is the world’s largest supplier of gel quality attapulgite (clay) and is the largest supplier of air-float kaolin to the glass manufacturing process. About Golden Gate Capital Golden Gate Capital is a San Francisco-based private equity investment firm with over $15 billion of capital under management. The principals of Golden Gate Capital have a long and successful history of investing across a wide range of industries and transaction types, including going-privates, corporate divest
Moody’s Analytics Earns #4 Spot in 2019 Chartis RiskTech100®19.11.2018 16:45 | Pressemelding
Moody’s Analytics, a global provider of financial intelligence, has been ranked #4 in the 2019 Chartis RiskTech100®, our best-ever finish. We also won awards in the Strategy category and in five solution categories: CECL, IFRS 9, Balance Sheet Risk Management, Credit Risk for the Banking Book, and Model Validation. This year, Moody’s Analytics earned a category award in one of the overall Chartis categories, Strategy, which considered our ability to execute, our vision and leadership, and our financial performance. Click here for more on our solution category wins. Now in its 13th year, the RiskTech100® evaluates technology companies that provide risk and compliance solutions to financial institutions. Moody’s Analytics has finished in the top five of these rankings for three straight years. “Moody’s Analytics continues to help its clients across the globe to satisfy their risk technology needs,” said Rob Stubbs, Head of Research at Chartis Research. “The breadth of its offerings is re
Moody’s Analytics Wins Five Solution Category Awards in 2019 Chartis RiskTech100®19.11.2018 16:45 | Pressemelding
Moody’s Analytics, a global provider of financial intelligence, has won five solution category awards in the 2019 Chartis RiskTech100®: CECL, IFRS 9, Balance Sheet Risk Management, Credit Risk for the Banking Book, and Model Validation. We also earned the #4 overall ranking – our highest-ever position and third straight top-five finish – and took the award in the Chartis Strategy category. Click here for more on our ranking and Chartis category win. “We’re honored by the recognition we received in this year’s RiskTech100®,” said Jacob Grotta, Managing Director-Head of Risk & Finance Analytics. “Winning five categories demonstrates that our solutions are empowering financial professionals across the lending, risk, and finance functions to make better, faster decisions.” We have now won the Credit Risk category for three straight years, reflecting both our deep credit experience and our continued investment and innovation in our wholesale and consumer credit assessment and origination so
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares19.11.2018 16:30 | Pressemelding
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) (“Axonics”), a medical technology company focused on the design, development and commercialization of innovative and minimally invasive sacral neuromodulation (“SNM”) solutions for the treatment of overactive bladder (“OAB”), fecal incontinence (“FI”), and urinary retention (“UR”), today announced that the underwriters of its initial public offering exercised in full their option to purchase an additional 1,200,000 shares of common stock from Axonics at the initial public offering price of $15.00 per share, less underwriting discounts and commissions. With this exercise, the total number of shares of common stock sold by Axonics in the offering increased to 9,200,000 shares, representing total gross proceeds of $138 million, before underwriting discounts and commissions and offering expenses. Axonics’ common stock began trading on The Nasdaq Global Select Market under the ticker symbol “AXNX” on October 31, 2018. BofA Merrill Lynch a